Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

Inclusion Criteria: * Patients at least 6 months post-transplantation and in stable clinical condition * Treatment with ECMPS doses between 720 mg/day and 1440 mg/day or MMF doses between1000 mg/day and 2000 mg/day, divided in two equal doses 12 hours apart and with no dose titrations planned for the duration of the trial * Ability to independently take medication * Successfully ingest a Placebo-IEM capsule with no difficulty Exclusion Criteria: * Inability to use the mobile phone provided for use in the clinical trial * Any episodes of acute rejection in the previous 3 months * Presence of cognitive impairment * Active alcohol or drug abuse * History of dysphagia, or inflammatory bowel disease, or gastrointestinal conditions or surgery that has modified the normal luminal flow of the gastrointestinal tract (e.g. Whipple procedure, bariatric surgery or Roux-en-Y) * Known allergies, including history of skin reactions to patches, that could preclude safe participation in the study Other protocol-defined inclusion/exclusion criteria may apply